Methotrexate

Generic Name: Methotrexate

Brand Names: Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₂N_₈O_₅

CAS Number: 59-05-2

Unique Ingredient Identifier: YL5FZ2Y5U1

Background: Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...

Indication: Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis

Associated Therapies: Medically induced abortion

Clinical Trials

Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus

Phase 4

Not yet recruiting

Conditions: Oral Lichen Planus

Interventions: Drug: Prednisolone
Drug: Apremilast
Drug: Methotrexate

First Posted Date: 2024-02-15

Last Posted Date: 2024-02-15

Lead Sponsor: All India Institute of Medical Sciences, Bhubaneswar

Target Recruit Count: 64

Registration Number: NCT06260904

Locations: 🇮🇳
AIIMS Bhubaneswar, Bhubaneswar, Odisha, India

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

Phase 2

Recruiting

Conditions: Hematologic Malignancy
Graft Versus Host Disease

Interventions: Drug: Methotrexate
Drug: Post-Transplant Cyclophosphamide
Drug: Fludarabine
Drug: Cycophosphamide
Drug: Anti-Thymoglobulin
Other: Donor Lymphocytes Injection
Radiation: total body irradiation
Other: hematopoietic stem cells
Drug: Thiotepa
Other: Graft nuclear cells
Drug: Busulfan
Drug: Clofarabine

First Posted Date: 2024-02-12

Last Posted Date: 2024-10-28

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 82

Registration Number: NCT06252870

Locations: 🇫🇷
CHU Angers, Angers, France
🇫🇷
CHU Brest, Brest, France
🇫🇷
CHU Nantes, Nantes, France

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Phase 1

Recruiting

Conditions: Recurrent Childhood Acute Myeloid Leukemia
Recurrent Childhood Myelodysplastic Syndrome
Recurrent Juvenile Myelomonocytic Leukemia
Refractory Childhood Acute Myeloid Leukemia
Refractory Childhood Myelodysplastic Syndrome
Refractory Juvenile Myelomonocytic Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cytarabine
Procedure: Echocardiography
Drug: Fludarabine
Drug: Hydrocortisone Sodium Succinate
Biological: Imetelstat
Drug: Leucovorin Calcium
Procedure: Lumbar Puncture
Drug: Methotrexate

First Posted Date: 2024-02-08

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 36

Registration Number: NCT06247787

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
C S Mott Children's Hospital, Ann Arbor, Michigan, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 10 locations

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

Phase 3

Recruiting

Conditions: Moderate to Severe Atopic Dermatitis

Interventions: Drug: Placebo
Drug: Methotrexate

First Posted Date: 2024-02-02

Last Posted Date: 2024-06-17

Lead Sponsor: medac GmbH

Target Recruit Count: 212

Registration Number: NCT06239311

Locations: 🇮🇹
Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
🇵🇱
Synexus Polska Sp. Z o.o. Odział w Warszawie, Warszawa, Poland
🇮🇹
Universita degli Studi della Campania "Luigi Vanvitelli" - Azienda Ospedaliera Universitaria, Naples, Italy

and more 27 locations

Paroxetine Safety and Efficacy in Rheumatoid Arthritis

Phase 3

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Methotrexate
Drug: Paroxetine

First Posted Date: 2024-01-30

Last Posted Date: 2024-02-02

Lead Sponsor: Mostafa Bahaa

Target Recruit Count: 100

Registration Number: NCT06231745

Locations: 🇪🇬
Mostafa Bahaa, Damietta, New Damietta, Egypt

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Phase 4

Recruiting

Conditions: Gout

Interventions: Biological: Pegloticase
Drug: Methotrexate

First Posted Date: 2024-01-29

Last Posted Date: 2024-12-13

Lead Sponsor: Amgen

Target Recruit Count: 240

Registration Number: NCT06229145

Locations: 🇺🇸
Altoona Center for Clinical Research - Research, Duncansville, Pennsylvania, United States
🇺🇸
The University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸
Orthopedic Physicians Alaska - Rheumatology and Infusion, Anchorage, Alaska, United States

and more 66 locations